Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2023 3
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures.
Wei F, Azuma K, Nakahara Y, Saito H, Matsuo N, Tagami T, Kouro T, Igarashi Y, Tokito T, Kato T, Kondo T, Murakami S, Usui R, Himuro H, Horaguchi S, Tsuji K, Murotani K, Ban T, Tamura T, Miyagi Y, Sasada T. Wei F, et al. Among authors: horaguchi s. J Immunother Cancer. 2023 Jul;11(7):e006788. doi: 10.1136/jitc-2023-006788. J Immunother Cancer. 2023. PMID: 37433717 Free PMC article.
Enhancing Mass spectrometry-based tumor immunopeptide identification: machine learning filter leveraging HLA binding affinity, aliphatic index and retention time deviation.
Wei F, Kouro T, Nakamura Y, Ueda H, Iiizumi S, Hasegawa K, Asahina Y, Kishida T, Morinaga S, Himuro H, Horaguchi S, Tsuji K, Mano Y, Nakamura N, Kawamura T, Sasada T. Wei F, et al. Among authors: horaguchi s. Comput Struct Biotechnol J. 2024 Feb 3;23:859-869. doi: 10.1016/j.csbj.2024.01.023. eCollection 2024 Dec. Comput Struct Biotechnol J. 2024. PMID: 38356658 Free PMC article.
Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors.
Nakahara Y, Kouro T, Motoyama S, Miura M, Fujita K, Igarashi Y, Higashijima N, Matsuo N, Himuro H, Wei F, Horaguchi S, Tsuji K, Mano Y, Komahashi M, Saito H, Azuma K, Sasada T. Nakahara Y, et al. Among authors: horaguchi s. Front Cell Dev Biol. 2024 Jan 16;11:1324898. doi: 10.3389/fcell.2023.1324898. eCollection 2023. Front Cell Dev Biol. 2024. PMID: 38469154 Free PMC article.
Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.
Himuro H, Nakahara Y, Igarashi Y, Kouro T, Higashijima N, Matsuo N, Murakami S, Wei F, Horaguchi S, Tsuji K, Mano Y, Saito H, Azuma K, Sasada T. Himuro H, et al. Among authors: horaguchi s. Cancer Immunol Immunother. 2023 Aug;72(8):2829-2840. doi: 10.1007/s00262-023-03464-w. Epub 2023 May 16. Cancer Immunol Immunother. 2023. PMID: 37188764 Free PMC article.
In vitro engineering of vascularized tissue surrogates.
Sakaguchi K, Shimizu T, Horaguchi S, Sekine H, Yamato M, Umezu M, Okano T. Sakaguchi K, et al. Among authors: horaguchi s. Sci Rep. 2013;3:1316. doi: 10.1038/srep01316. Sci Rep. 2013. PMID: 23419835 Free PMC article.
Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Horaguchi S, Nakahara Y, Igarashi Y, Kouro T, Wei F, Murotani K, Udagawa S, Higashijima N, Matsuo N, Murakami S, Kato T, Kondo T, Xiang H, Kasajima R, Himuro H, Tsuji K, Mano Y, Komahashi M, Miyagi Y, Saito H, Azuma K, Uehara S, Sasada T. Horaguchi S, et al. Biomedicines. 2024 Aug 12;12(8):1831. doi: 10.3390/biomedicines12081831. Biomedicines. 2024. PMID: 39200295 Free PMC article.